---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-085864"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:22:26.987135+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics reports Q2 net loss $26.8M, cash $372.8M; Genentech expands collaboration

## Summary
- Net loss $26.8M ($0.90/share) vs $17.9M ($0.74) in Q2 2021, driven by higher R&D and G&A costs.
- Cash $372.8M as of June 30, 2022, down from $438.7M; expected runway into 2025.
- Genentech exercised option to expand immuno-oncology collaboration, triggering $10M payment to Bicycle in Q3 2022.
- BT8009 Phase I interim data: 50% ORR in urothelial cancer at 5.0mg/m2 weekly; four of five responders on therapy >24 weeks.
- Expansion cohorts of BT5528 Phase I/II trial initiated; BT7480 Phase I/II poster presented at ASCO 2022.

## SEC filing metadata
- accession: 0001104659-22-085864
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465922085864/0001104659-22-085864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465922085864/tm2222487d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-085864
- JSON: https://secwatch.observer/filing/0001104659-22-085864.json
- Plain text: https://secwatch.observer/filing/0001104659-22-085864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.